GRAIL to Announce Third Quarter 2024 Financial Results
GRAIL (Nasdaq: GRAL) has scheduled the release of its third quarter 2024 financial results after market close on Tuesday, November 12, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) has scheduled the release of its third quarter 2024 financial results after market close on Tuesday, November 12, 2024. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and business progress. Interested parties can access the live webcast and replay through the investor relations section at investors.grail.com, with registration available at the provided link. Participants are advised to register and join ten minutes before the scheduled start time.
Details
News Market Reaction – GRAL
The recorded move for GRAL in the trading session of this news was +4.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Third Quarter 2024 Webcast and Conference Call Details
A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com.
Please register for the live event at https://grail-q3-financial-results-2024.open-exchange.net/.
To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-announce-third-quarter-2024-financial-results-302290446.html
SOURCE GRAIL, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.